NovMetaPharma Co., Ltd.

A229500

KR7229500004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-06-27 EDT			5-day change	1st Jan Change
6,970 ^KRW	+3.72%		-4.52%	-66.00%

05-27	NovMetaPharma Co., Ltd. cancelled the acquisition of SK Securities No.8 Special Purpose Acquisition Company in a reverse merger transaction.	CI
2023	NovMetaPharma Co., Ltd. agreed to acquire SK Securities No.8 Special Purpose Acquisition Company in a reverse merger transaction	CI

NovMetaPharma Co., Ltd. announced that it has received KRW 3.8000182 billion in funding from Heungkuk Life Insurance Co., Ltd.

November 18, 2021

On November 19, 2021, NovMetaPharma Co., Ltd. closed the transaction.

Latest news about NovMetaPharma Co., Ltd.

NovMetaPharma Co., Ltd. cancelled the acquisition of SK Securities No.8 Special Purpose Acquisition Company in a reverse merger transaction.	05-26	CI
NovMetaPharma Co., Ltd. agreed to acquire SK Securities No.8 Special Purpose Acquisition Company in a reverse merger transaction	23-07-26	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 6.99999258 billion in funding from BNC Korea Co., Ltd.	23-06-28	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 6.99999258 billion in funding from BNC Korea Co., Ltd.	23-06-20	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 3.299969948 billion in funding from Road Jeilho Bio Private Equity Joint Venture Company	23-03-28	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 3.299969948 billion in funding from Road Jeilho Bio Private Equity Joint Venture Company and other investors	23-03-06	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 3.8000182 billion in funding from Heungkuk Life Insurance Co., Ltd.	21-11-18	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 3.8000182 billion in funding from Heungkuk Life Insurance Co., Ltd.	21-11-10	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 3 billion in funding	21-08-19	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 3 billion in funding	21-08-17	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 4.511234288 billion in funding from Intellectual Discovery Co., Ltd.	19-04-18	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 4.511234288 billion in funding from Intellectual Discovery Co., Ltd.	19-04-07	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 10.22 billion in funding from KMH Co. Ltd., Whale Investment and other investors	17-12-05	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 10.22 billion in funding from KMH Co. Ltd., Whale Investment and other investors	17-12-04	CI
NovMetaPharma Co., Ltd. announced that it has received KRW 1.86 billion in funding	17-08-24	CI
NovMetaPharma Co., Ltd. announced that it expects to receive KRW 1.86 billion in funding	17-08-23	CI

NovMetaPharma Co., Ltd. is a Korea-based company mainly engaged in the development and sale of pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment is involved in the development and sale of diabetes treatment, obesity treatment, osteoporosis treatment, alzheimer's disease treatment, and autoimmune enhancers. The Health Functional Food segment is engaged in the manufacturing and sale of health functional food related to blood sugar, prostate health, comprehensive minerals, and cognitive improvement. It also produces and sells vinegar drinks. The Company distributes its products within the domestic market and to overseas markets, including America and China.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NOVMETAPHARMA CO., LTD.	-66.00%	45.33M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs